TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.
Brian D LehmannVandana G AbramsonMelinda E SandersErica L MayerTufia C HaddadRita NandaCatherine Van PoznakAnna Maria StornioloJulie R NangiaPaula I Gonzalez EricssonVioleta SanchezKimberly N JohnsonRichard G AbramsonSheau-Chiann ChenYu ShyrCarlos L ArteagaAntonio C WolffJennifer A Pietenpolnull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The combination of enzalutamide and taselisib increased CBR in TNBC patients with AR+ tumors. Correlative analyses suggest AR protein expression alone is insufficient for identifying patients with AR-dependent tumors and knowledge of tumor LAR subtype and AR splice variants may identify patients more or less likely to benefit from AR antagonists.